Liquid biopsy for early detection of pancreatic ductal adenocarcinoma

An exosome-based biomarker (PANXEON) combined with carbohydrate antigen 19-9 detected early-stage pancreatic ductal adenocarcinoma with high sensitivity in a prospective study of 1,785 individuals across four countries. Late diagnosis remains the main driver of poor outcomes in this cancer, which is what a blood-based test is meant to address. This is a diagnostic accuracy study rather than a randomised trial: no survival benefit from earlier detection has been demonstrated, and the panel awaits independent validation. The work was published in Nature Medicine (2026).